Gene-Disorder Association · Article
Gene
RET Ret Proto-Oncogene
×
First reported
1991
Supporting publications
42
Manually curated Approved treatment annotated
Association Review
In brief The association between RET (Ret Proto-Oncogene) and Thyroid Cancer is a manually-curated gene–disease association, with its 2 contributing sources — 1 of them expert-curated — recording pathogenic variants.
Sources
2
Clinical variants
1
Symptoms
6
Compounds
4
Trials
42 of 1,023 via RET compounds
Publications
42
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 2 sources
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Thyroid Cancer
The disorder 13 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
ClinVar and variant evidence
Genetic basis 1 clinical variant
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access
06
Interventions
Therapeutics 4 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 1,023 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
42 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 16 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access